Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7344731 | 0.96 | LMNA (0.52) | LMNAALDH1A1TSHR | |
| Butane SCHEMBL8184201 | 0.92 | LMNA (0.48) | LMNAALDH1A1TSHR | |
| Ethylene SCHEMBL5155337 | 0.85 | LMNA (0.55) | LMNA | |
| Glutaral SCHEMBL6229345 | 0.83 | LMNA (0.52) | LMNAALDH1A1TSHR | |
| Glutaral SCHEMBL7886922 | 0.83 | LMNA (0.52) | LMNAALDH1A1TSHR | |
| Butanal SCHEMBL9765982 | 0.83 | LMNA (0.52) | LMNAALDH1A1TSHR | |
| SCHEMBL11485155 | 0.83 | LMNA (0.63) | LMNAALDH1A1TSHR | |
| SCHEMBL9657661 | 0.82 | LMNA (0.46) | LMNAALDH1A1TSHR | |
| SCHEMBL188914 | 0.81 | LMNA (0.60) | LMNAALDH1A1 | |
| Ethylene SCHEMBL11409706 | 0.80 | LMNA (0.48) | LMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190336610-A1 | GLUCOSE-SENSITIVE PEPTIDE HORMONES | GUBRA APS (DK) | 2019-11-07 | — | — | US | disclosed |
| EP-3558383-A1 | GLUCOSE-SENSITIVE PEPTIDE HORMONES | Gubra ApS (DK) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018115462-A1 | GLUCOSE-SENSITIVE PEPTIDE HORMONES | GUBRA APS (DK) | 2018-06-28 | — | — | WO | disclosed |
| EP-0001668-B1 | CYCLISATION PROCESS FOR PREPARING 11 BETA-AXIALLY-SUBSTITUTED STEROIDS | AKZO N.V. (NL) | 1983-05-25 | — | — | EP | disclosed |
| US-4329473-A | HYPOTENSIVE AGENTS | SRI INTERNATIONAL | 1982-05-11 | — | — | US | disclosed |
| US-4222940-A | Cyclization substrates, cyclization process and related 11β-axially-substituted steroids | AKZONA INCORPORATED (US) | 1980-09-16 | — | — | US | disclosed |
| EP-0001668-A2 | Cyclisation process for preparing 11 beta-axially-substituted steroids | AKZO N.V. (NL) | 1979-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336610-A1 | GLUCOSE-SENSITIVE PEPTIDE HORMONES | IAPP, GCG, VIP | LMNA 456/4885ALDH1A1 3127/4885TSHR 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.